Addictive Behaviors, Journal Year: 2024, Volume and Issue: 157, P. 108095 - 108095
Published: June 19, 2024
Language: Английский
Molecular Psychiatry, Journal Year: 2024, Volume and Issue: 29(8), P. 2587 - 2598
Published: March 14, 2024
Cannabis is the most frequently used illicit drug in United States with more than 45 million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high prevalence, there are currently no FDA-approved medications for CUD. Patients treated semaglutide, glucagon-like peptide-1 receptor agonist (GLP-1RA) approved treating type 2 diabetes (T2D) and weight management have reported reduced desire to drink smoke. Preclinical studies shown that semaglutide decreased nicotine alcohol consumption. preliminary clinical evidence semaglutide's potential beneficial effects on various substance disorders led us evaluate if it pertained In this retrospective cohort study electronic health records (EHRs) TriNetX Analytics Network, global federated research network approximately 105.3 patients 61 large healthcare organizations US, we aimed assess associations both incident recurrent CUD diagnosis compared non-GLP-1RA anti-obesity or anti-diabetes medications. Hazard ratio (HR) 95% confidence intervals (CI) were calculated 12-month follow-up by comparing propensity-score matched patient cohorts. The population included 85,223 obesity who prescribed medications, findings replicated 596,045 T2D. (mean age 51.3 years, 65.6% women), was associated lower risk prior history (HR: 0.56, CI: 0.42-0.75), 0.62, 0.46-0.84). Consistent reductions seen stratified gender, group, race without Similar T2D when 0.40, 0.29-0.56) 0.66, 0.42-1.03). While these provide benefit real-world populations, further preclinical warranted understand underlying mechanism randomized trials needed support clinically
Language: Английский
Citations
24
JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(2), P. e2457868 - e2457868
Published: Feb. 4, 2025
Importance Despite public health concerns that cannabis legalization may increase the number of cases schizophrenia caused by cannabis, there is limited evidence on this topic. Objective To examine changes in population-attributable risk fraction (PARF) for use disorder (CUD) associated with after liberalization medical and nonmedical Canada. Design, Setting, Participants This population-based cohort study was conducted Ontario, Canada, from January 1, 2006, to December 31, 2022, among 13 588 681 people aged 14 65 years without a history schizophrenia. Exposures Diagnosis CUD emergency department or hospital setting ( International Statistical Classification Diseases Related Health Problems, Tenth Revision, Canada [ ICD-10-CA ] codes F12x T40.7). Main Outcome Measures Changes PARF F20x F25x Diagnostic Manual Mental Disorders [Fourth Edition] DSM-IV code 295x) over 3 policy periods: prelegalization (January 2006 November 2015), (December 2015 September 2018), (October 2018 2022). A secondary outcome diagnosis psychosis not otherwise specified (NOS) F29x 298x). Segmented linear regression used 2018. Results The included individuals (mean [SD] age, 39.3 [16.1] years; 6 804 906 males [50.1%]), whom 118 650 (0.9%) had CUD. total 91 106 (0.7%) developed (80 523 470 031 [0.6%] general population vs 10 583 [8.9%] CUD). almost tripled 3.7% (95% CI, 2.7%-4.7%) during period 10.3% 8.9%-11.7%) period. postlegalization ranged 18.9% 16.8%-21.0%) 19 24 1.8% 1.1%-2.6%) females 45 years. annual incidence stable time, while NOS increased 30.0 55.1 per 100 000 (83.7%) relative steadily no accelerations changes, increases accelerated liberalization. Conclusions Relevance In proportion incident substantial policy. Ongoing research indicated understand long-term associations prevalence psychotic disorders.
Language: Английский
Citations
4
American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(1), P. 21 - 32
Published: Jan. 1, 2025
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain are effective safe treatment of major depressive disorder, treatment-resistant depression, posttraumatic stress disorder. Preliminary evidence also supports efficacy other disorders (e.g., tobacco alcohol use disorders). Notwithstanding promise psychedelics, concerns have arisen with respect to interpretability translatability study results. For example, aspects related short- long-term safety, abuse liability, essentiality psychedelic "trip" psychological support are, inter alia, insufficiently characterized agents. The overarching aims this overview 1) review methodological affect inferences interpretation extant studies disorders, 2) provide guidance future development psychiatry, critical clinical implementation.
Language: Английский
Citations
3
JAMA Psychiatry, Journal Year: 2025, Volume and Issue: 82(3), P. 319 - 319
Published: Jan. 22, 2025
This cross-sectional study assesses differences in cannabis use frequency and prevalence of disorder between medical-only, medical-nonmedical, nonmedical-only among US adults.
Language: Английский
Citations
2
The Journal of Behavioral Health Services & Research, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 11, 2025
Language: Английский
Citations
2
European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 19, 2024
Abstract The legalization of cannabis for medical and recreational purposes has progressed internationally. Cannabis cannabinoids are advocated a plethora indications. An increasing number nonmedical users regularly consume large doses delta-9-Tetrahydrocannabinol (THC), the main active component cannabis. Aim: to summarize evidence on (1) risks use (2) effectiveness safety medicinal Findings use: is mostly used experience its acute rewarding effects. Regular high THC products can produce addiction (cannabis disorder or CUD). Acute consumption (including unintentionally) cause time-limited mental, gastrointestinal, cardiovascular problems motor vehicle accidents. Chronic patterns have been associated with multiple adverse outcomes that particular concern among adolescents young adults, such as, disrupted learning, impaired cognitive performance, reduced educational attainment an increased risk CUD, psychosis/schizophrenia, mood anxiety disorders suicidal behaviors. There debate about extent which these outcomes. Physical health (e.g., respiratory cardiovascular, prematurity restricted fetal growth, hyperemesis syndrome others) also linked repeated content. Herbal cannabis, medicines from extracted synthetized cannabinoids—often as adjuvants standard medicines—may small modest benefits. This primarily case in treating chronic pain, muscle spasticity, chemotherapy-induced nausea vomiting, refractory epilepsy (in cannabidiol, CBD). inconclusive their value mental other conditions. Safety: Cannabis-based medicine generally well tolerated. mild moderate effects CUD.
Language: Английский
Citations
13
Journal of Neural Transmission, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 23, 2025
Abstract The majority of patients with cannabis use disorder (CUD) regularly take medication. Cannabinoids influence metabolism some commonly prescribed drugs. However, little is known about the characteristics and frequency potential cannabis-drug (CDIs) drug-drug interactions (DDIs) in CUD. Therefore, our study aimed to determine prevalence drug CUD during inpatient treatment on an addiction-specific ward over a six-year-period. To this aim, medication charts were analyzed screened for CDIs DDIs. Herein, drugs.com classification UpToDate Lexicomp program DDIs utilized. cohort consisted 301 patient cases, predominantly male (85.0%), median age 37 years. 89.4% (269/301) all cases involved taking at least one that could potentially interact cannabis. Levomethadone, buprenorphine morphine most common drugs serious CDIs. In addition, 196 identified, which 25.5% classified as ‘avoid combination’ 74.5% ‘consider therapy modification’. Hereby, combinations levomethadone other psychotropic frequently accounted severe mild results indicate especially diagnosed also receiving opioid substitution are risk interactions. clinical monitoring vigilance respiratory function should be applied treatment. Routine interaction check tools considered by healthcare providers. therapeutic (TDM) used increase safety population.
Language: Английский
Citations
1
Psychological Medicine, Journal Year: 2024, Volume and Issue: 54(11), P. 2926 - 2936
Published: May 22, 2024
Abstract Background Epidemiologic research suggests that youth cannabis use is associated with psychotic disorders. However, current evidence based heavily on 20th-century data when was substantially less potent than today. Methods We linked population-based survey from 2009 to 2012 records of health services covered under universal healthcare in Ontario, Canada, up 2018. The cohort included respondents aged 12–24 years at baseline no prior disorder ( N = 11 363). primary outcome days first hospitalization, ED visit, or outpatient visit related a according validated diagnostic codes. Due non-proportional hazards, we estimated age-specific hazard ratios during adolescence (12–19 years) and young adulthood (20–33 years). Sensitivity analyses explored alternative model conditions including restricting the hospitalizations visits increase specificity. Results Compared use, significantly disorders (aHR 11.2; 95% CI 4.6–27.3), but not 1.3; 0.6–2.6). When restricted only, strength association increased markedly 26.7; 7.7–92.8) did change meaningfully 1.8; 0.6–5.4). Conclusions This study provides new strong age-dependent between risk disorder, consistent neurodevelopmental theory vulnerable time cannabis. notably greater previous studies, possibly reflecting recent rise potency.
Language: Английский
Citations
8
PLoS ONE, Journal Year: 2024, Volume and Issue: 19(3), P. e0298697 - e0298697
Published: March 27, 2024
Global cannabis use has risen 23% since 2010, with 209 million reported users, most of whom are males reproductive age. Delta-9-tetrahydrocannabinol (THC), the main psychoactive phytocannabinoid in cannabis, disrupts pro-homeostatic functions endocannabinoid system (ECS) within male system. The ECS is highly involved regulating morpho-functional and intrinsic sperm features that required for fertilization pre-implantation embryo development. Previous work by our group demonstrated THC altered capacitation transcriptome, including several fertility-associated microRNAs (miRs). Despite prevalent among age, clinical pre-clinical research investigating impact paternal on function outcomes artificial technologies (ARTs) remains inconclusive. Therefore, present study investigates vitro exposure functions, contributions to development following IVF. Bovine were used as a translational model human treated concentrations reflect plasma levels after therapeutic (0.032μM), low (0.32μM)-high (4.8μM) recreational use. After 6-hours treatment, did not alter acrosomal reaction, but 4.8μM significantly reduced mitochondrial membrane potential (MMP) (p<0.05), primarily through agonistic interactions CB-receptors. Fertilization bovine oocytes THC-treated developmental rates, blastocysts generated from 0.32–4.8μM had fewer trophoblasts while exposed any concentration cells inner cell mass (ICM), particularly 0.032μM (p<0.001). Fertility associated miRs, miR-346, miR-324, miR-33b, miR-34c analyzed THC-exposed IVF, lower miRs-346, -324, -33b found 0.32μM THC, higher (p<0.05). Levels miR-346 also Our findings suggest may key epigenetic factors This first demonstrate negatively affects quality
Language: Английский
Citations
5
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Journal Year: 2025, Volume and Issue: unknown
Published: April 15, 2025
Citations
0